Every listed Indian CDMO company covered here — Divi's Laboratories, Anthem, Blue Jet, Cohance, Gland, Neuland, Piramal Pharma, Sai Life, Shilpa, Syngene — against Laurus, on the same numbers from the same filings. Click a column to rank by it. Tick up to three and press Compare for the full side-by-side.
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | ₹248.3k Cr | 96.7× | 12.8% | 32.6% | 21.5% | 0.9× | 0.0× | 53.5% | |
| vs | 2Laurus | ₹108.3k Cr | 121.9× | 22.7% | 26.2% | 18.0% | 2.1× | 0.5× | 122.0% |
| 3 | ₹50.1k Cr | 84.6× | 15.2% | 39.3% | 29.6% | 0.9× | 0.0× | 7.3% | |
| 4 | ₹48.1k Cr | 46.8× | 14.5% | 25.3% | 14.9% | 1.2× | 0.0× | 44.8% | |
| 5 | ₹33.9k Cr | 97.2× | 29.4% | 28.8% | 19.2% | 1.8× | 0.1× | 83.1% | |
| 6 | ₹28.9k Cr | 79.3× | 37.0% | 28.7% | 26.6% | 1.0× | 0.2× | 47.3% | |
| 7 | ₹27.9k Cr | n/m | -3.1% | 10.4% | 1.2% | n/m | 0.7× | 3.7% | |
| 8 | ₹20.2k Cr | 83.0× | 19.9% | 28.3% | 11.4% | 1.7× | 0.3× | 152.5% | |
| 9 | ₹17.3k Cr | 96.6× | -13.0% | 18.8% | 5.8% | 1.4× | 0.1× | -49.8% | |
| 10 | ₹15.2k Cr | 48.0× | 2.6% | 24.6% | 8.7% | 2.4× | 0.1× | -42.4% | |
| 11 | ₹10.2k Cr | 41.1× | -8.0% | 31.0% | 26.5% | 0.9× | 0.0× | -12.2% |
Market cap, P/E and the 12-month return move with the market and are dated to the last close. Every other column is the last full financial year. n/m — loss-making, so the multiple means nothing. A dash means not recorded, which is not the same as nil.
| Metric | LAURUSLABS | DIVISLAB |
|---|---|---|
| What you pay22 Sept 2026 | ||
| Share price | ₹2,006.50 | ₹9,352.00 |
| Market cap | ₹1,08,331 Cr | ₹2,48,296 Cr |
| P/E | 121.89× | 96.69× |
| P/B | 20.44× | 14.81× |
| P/S | 15.90× | 23.51× |
| 12-month return | 122.0% | 53.5% |
| SizeFY26 | ||
| Revenue | ₹6,813 Cr | ₹10,560 Cr |
| PAT | ₹889 Cr | ₹2,568 Cr |
| Net worth | ₹5,300 Cr | ₹16,761 Cr |
| Gross block | ₹4,371 Cr | ₹6,528 Cr |
| GrowthFY26 | ||
| Revenue growth | 22.7% | 12.8% |
| Revenue CAGR (3y) | 4.1% | 10.8% |
| PAT CAGR (3y) | 4.0% | 12.1% |
| What it keepsFY26 | ||
| EBITDA margin | 26.2% | 32.6% |
| PAT margin | 13.0% | 24.3% |
| ROCE | 18.0% | 21.5% |
| ROE | 16.8% | 15.3% |
| CFO / PAT (3y) | 2.05× | 0.89× |
| What it owesFY26 | ||
| Net debt | ₹2,405 Cr | ₹-3,407 Cr |
| Debt / equity | 0.48× | 0.00× |
| CWIP | ₹773 Cr | ₹2,113 Cr |
| Debtor days | 115 days | 103 days |
| Who owns itFY26 | ||
| Promoter holding | 27.5% | 51.9% |
| Institutional holding | 41.7% | 39.6% |
Every figure comes from the same filings the company pages are built from. A dash means the figure is not recorded, which is not the same as nil.
Laurus makes the active ingredients inside medicines, and increasingly makes the finished medicines for other companies too. Affordable medicines, largely HIV treatments, were 57% of June-quarter revenue; contract manufacturing was 43% and growing at 69%. Fifteen manufacturing sites, 8,126 people, more than 1,540 of them scientists.
Divi's makes the active ingredients inside medicines. Half the business supplies generic drug makers at very large scale; the other half is custom synthesis, making patented molecules to order for the companies that invented them. Plants in Andhra Pradesh and Telangana, selling mostly to Europe and America, on half as much revenue again as its nearest listed rival.
More than ₹4,700 crore has gone into plants over five years, over 85% of it into growth rather than upkeep, with new capacity at Vizag and a joint venture with KRKA at Hyderabad. Fifty-four inspections passed by the American, WHO, European and Japanese regulators, and 92 drug master files. What is being built next is antibody-drug conjugates through the Aarvik agreement, gene therapy, and 500 acres just handed over in Andhra Pradesh.
Gross fixed assets rose 20% last year, with three major capital programmes close to finishing and under regulatory validation, and a new site at Kakinada doing backward-integration work while it waits to be qualified for commercial supply. There are no acquisitions and two subsidiaries. Peptides are the main area of investment, with capacity being added in both solid-phase and liquid-phase synthesis.
Founder Dr Satyanarayana Chava runs it, and since April 2024 two more of his family have held executive director seats — three of the five. The promoter group owns 27.47% across several vehicles, though the founder's own family holds about 23.3% of that, and a small parcel of 0.74% is given as loan security. Pay is the line worth watching: ₹74 crore between five executive directors and one relative, the founder's own up 65% to ₹38.12 crore.
Founder Dr Murali K. Divi remains managing director, his son Dr Kiran S. Divi is chief executive and his daughter Nilima Prasad Divi is commercial director — the three senior operating roles held by one family, which owns 51.88% of the shares. Six independent directors sit alongside them. The family takes ₹224 crore of pay, about 9% of profit, and ₹347 crore of dividend on the stake it owns.
On a big pharma client onboarded in the quarter — “significant opportunities ahead of us.”
Dr Satyanarayana Chava · Q1 FY27 earnings call
Asked directly about concentration: none of consequence by programme, customer or therapeutic area, and contract work is predominantly on-patent innovator molecules.
Q1 FY27 earnings call
Custom synthesis rose sharply in the June quarter — before the three big expansion projects have contributed anything.
Q1 FY27 earnings call
Long-term contracts for iodine-based contrast media are being signed with two customers, one already in commercial supply.
Q1 FY27 earnings call
Closing prices to 22 Sept 2026, adjusted for bonuses and splits. Dividends are not counted. This is what happened, not what will.
A sector, read end to end, and the companies as they are published. Roughly monthly. Nothing else, and one click to stop.